###begin article-title 0
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 642 648 642 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 821 827 817 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 963 969 955 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1037 1043 1029 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1102 1108 1094 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1218 1224 1206 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1234 1241 1222 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1293 1299 1281 1287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 527 530 <span type="species:ncbi:9606">man</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
S100A2 is generally found expressed in the epidermis and was recently shown to play a crucial role in the differentiation of keratinocytes. Also known as CaN19, S100A2 was identified as a potential tumor suppressor. Expression of S100A2 is upregulated by p53. The proteins p63 and p73 are related to p53 and are expressed as several splice variants with partially overlapping tasks but also functions different from p53. It had been shown that p63 proteins with mutations in their DNA-binding domain cause severe phenotypes in man as autosomal dominantly inherited disease including EEC, AEC, SHFM, LMS and ADULT syndromes. Here we show that S100A2 is a transcriptional target of p63/p73 family members, particularly the p63 splice variant TAp63gamma. The regulation is mediated by a novel transcriptional element in the S100A2 promoter which is bound by TAp63gamma but not by p53. Mutant p63 proteins derived from EEC and ADULT syndrome patients cannot activate S100A2 transcription whereas SHFM-related mutants still can stimulate the S100A2 promoter. Consistent with a function in tumor suppression S100A2 expression is stimulated upon DNA damage. After doxorubicin treatment p63gamma proteins are recruited to the S100A2 promoter in vivo. This may indicate a function of the p63-dependent S100A2 regulation in tumor suppression.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 51 52 51 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 407 408 407 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 31 37 <span type="species:ncbi:9913">bovine</span>
S100A2 was first isolated from bovine lung tissue (1) and is generally found expressed in the epidermis (2). Recently, S100A2 was shown to play a crucial role during differentiation when its expression silenced by siRNA-mediated mRNA knockdown resulted in decreased expression of two keratinocyte differentiation markers (3). In contrast to other S100 family members, S100A2 is located in the cell nucleus (4,5) and is involved in keratinocyte response to oxidative stress (6).
###end p 4
###begin p 5
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 212 214 212 214 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 270 272 270 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 335 337 335 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 344 346 344 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 365 371 365 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 444 445 444 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 466 468 466 468 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 475 477 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
S100A2 is a member of the S100 family representing the largest family within the EF-hand proteins. These proteins are characterized by two distinct EF-hand motifs (7) flanking a central hinge region and act as Ca2+ signaling or Ca2+ buffering proteins. In addition to Ca2+ many S100 family members display high affinity also towards Zn2+ and Cu2+ ions. The cDNA of S100A2 codes for a 10.7-kDa protein which can form homodimers in living cells (8) with affinity to Ca2+ and Zn2+ ions (9). Dimerization of S100 proteins appears to be important for their biological function.
###end p 5
###begin p 6
###xml 372 374 372 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 848 850 848 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 437 442 <span type="species:ncbi:9606">human</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
Members of the S100 family show a large diversity in structure and function. They are involved in the regulation of contraction, motility, cell growth, differentiation, cell cycle progression, transcription and secretion. In contrast to other EF-hand proteins, S100 proteins have so far been found only in vertebrates and consequently form a phylogenetically young group (10). Genes of most group members are clustered in region 1q21 of human chromosome 1 which is known as epidermal differentiation complex EDC (11). An analogous cluster is found on chromosome 3 in mice. Usually the highly conserved gene structure consists of three exons of which the first exon is noncoding. Furthermore, S100 proteins are expressed in a cell and tissue-specific manner (12) implying that the relatively large number of family members is not due to redundancy (13).
###end p 6
###begin p 7
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CaN19</italic>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 204 210 204 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 274 279 274 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15 B16 B17 B18">15&#8211;18</xref>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 459 465 459 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 867 869 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 958 974 958 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cyclooxygenase-2</italic>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 149 154 <span type="species:ncbi:9606">human</span>
Interestingly, S100A2-then named CaN19-was identified as a potential tumor suppressor gene by differential expression in normal versus tumor-derived human mammary epithelial cells (14). It was shown that S100A2 expression is markedly downregulated in several tumor tissues (15-18). Methylation of the promoter mediates S100A2 repression during breast cancer progression (19). Furthermore, it was shown that the tumor suppressor p53 activates transcription of S100A2 (20). In addition, S100A2 overexpression was found in gastric cancer (21), ovarian cancer (22), lymphoma (23), head and neck squamous cell carcinoma (24,25) and early-stage nonsmall cell lung cancer (26). It was concluded that overexpression of S100A2 may be an early tumorigenic event (21). Another finding is that S100A2 modulates transcriptional activity of p53 due to protein-protein interaction (27). Recently it was shown that S100A2 could exert its antitumor activity by repression of cyclooxygenase-2 expression (28).
###end p 7
###begin p 8
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 262 267 262 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30 B31 B32 B33">30&#8211;33</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1013 1018 1013 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35 B36 B37 B38 B39 B40 B41">35&#8211;41</xref>
###xml 1125 1127 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1128 1130 1128 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 788 791 <span type="species:ncbi:9606">man</span>
Many biological processes like apoptosis and development are critically regulated by members of the p53 family (29). p63 and p73 are a group of proteins that, like p53, are transcription factors which activate target genes through sequence-specific DNA binding (30-33). The high level of amino acid sequence similarity within the p53 family, particularly in the DNA-binding domain, allows transactivation of common target genes. However, members of the p53 family are not entirely functionally redundant. While p53 is known as a classical tumor suppressor, p63 seems to be capable of enforcing some of the tumor suppressive mechanisms that p53 also mediates (34). Furthermore, p63 plays an important role in development. Mutations in the p63 DNA-binding domain cause severe phenotypes in man as autosomal dominantly inherited syndromes. This family of disorders includes the EEC, AEC, SHFM, LMS and ADULT syndromes. They are characterized by combination of ectrodactyly, ectodermal dysplasia and facial clefting (35-41). Recently, it was shown that p63 is able to bind DNA elements which differ from classical p53 consensus (42,43). This implies that p53 and p63 can regulate different target genes.
###end p 8
###begin p 9
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 183 189 179 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 271 277 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 327 333 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 147 152 <span type="species:ncbi:9606">human</span>
Here we identify S100A2 as a novel transcriptional target of the p63 isoform TAp63gamma. We show that mutants of p63 which are responsible for the human EEC syndrome fail to activate S100A2 transcription. In addition, we find that recruitment of p63gamma proteins to the S100A2 promoter correlates with increased expression of S100A2 following DNA damage.
###end p 9
###begin title 10
MATERIALS AND METHODS
###end title 10
###begin title 11
Cell culture, transfections and luciferase assays
###end title 11
###begin p 12
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63</italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 469 472 469 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p73</italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
SaOS-2 cells obtained from DSMZ (Braunschweig, Germany) were cultured and transfected in 24-well plates as described previously (44). DLD-1 cells stably transfected with various p53 family-expressing plasmids were cultured as described previously (44). DLD-1 cells express only inactive mutant p53 protein (45) and display a single nucleotide exchange in one p63 allele resulting in a replacement of proline at position 279 in the TA*p63 protein by histidine (46). The p73 gene in DLD-1 cells is wild type (47).
###end p 12
###begin p 13
###xml 252 258 252 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 246 251 <span type="species:ncbi:9606">human</span>
Transient transfections using expression plasmids for wild-type and mutant p53 family members (25 ng) were carried out according to the manufacturer's instructions using Fugene 6 (Roche, Mannheim, Germany) with 400 ng of the plasmid carrying the human S100A2 promoter and 25 ng pRL-null vector (Promega, Mannheim, Germany) per assay. The total amount of transfected DNA was held constant. Luciferase assays were carried out as reported earlier (48).
###end p 13
###begin p 14
###xml 10 13 10 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 36 38 36 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
HepG2 and p53-negative Hep3B cells (49) were also obtained from DSMZ and cultured as described (46). As a DNA-damaging agent, doxorubicin was employed at 0.2 ng/ml.
###end p 14
###begin title 15
RNA extraction and real-time RT-PCR
###end title 15
###begin p 16
###xml 163 166 163 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 321 326 321 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50 B51 B52">50&#8211;52</xref>
###xml 356 362 356 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 350 355 <span type="species:ncbi:9606">human</span>
Extraction of total RNA was performed employing the RNeasy Protect Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Cells carrying p53 family transgenes used for RNA preparations were described earlier (44). Real-time RT-PCR mRNA quantification including calculations have been described (50-52). Specific primers for human S100A2 5'-GCG ACA AGT TCA AGC TGA GT-3'; 5'-CAC CTG CTG GTC ACT GTT CT-3' (GenBank accession number NM_005978) were used at 1 microM on 50 ng total RNA template in the QuantiTect SYBR Green RT-PCR mix (Qiagen, Hilden, Germany) employing a LightCycler instrument (Roche).
###end p 16
###begin title 17
###xml 51 56 <span type="species:ncbi:9606">human</span>
Generation of polyclonal antibodies raised against human S100A2
###end title 17
###begin p 18
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 322 338 322 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 386 392 386 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">600 nm</sub>
###xml 485 486 482 483 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 41 46 <span type="species:ncbi:9606">human</span>
###xml 322 343 <span type="species:ncbi:511693">Escherichia coli BL21</span>
###xml 1018 1024 <span type="species:ncbi:9986">rabbit</span>
Full-length cDNA of S100A2 prepared from human blood RNA where amplified using the primer 5'-AAA CCA TGG GCA GTT CTC TGG AGC AG 3' and 5'-TTT CTC GAG GGG TCG GTC TGG GCA GC-3'. The fragment was cloned into the NcoI/XhoI site of the pTriEx-2 expression vector (Novagen, Madison, WI, USA). The plasmid was used to transform Escherichia coli BL21 cells. Cells were grown to a density of OD600 nm of 0.5 and expression of recombinant protein was induced by adding 1 mM isopropyl thio-beta-d-galactopyranoside (IPTG) to the culture for 4 h. Cells were harvested by centrifugation and cell lysates were used for Ni-His-affinity chromatography purification. The eluate was further purified using preparative SDS-PAGE. Bands carrying S100A2 were cut out from the gel, ground in a mortar in liquid nitrogen and suspended in PBS. For immunization the antigen suspension was mixed with an equal volume of the adjuvant TiterMax(R) Gold (CytRx Corporation, Los Angeles, CA, USA) and injected subcutaneously into the neck area of a rabbit. In intervals of 4 weeks antibody quality was tested by using decreasing amounts of recombinant protein in western blot analyses. Antiserum obtained after five immunizations was used for western blot analysis.
###end p 18
###begin title 19
Western blot analysis
###end title 19
###begin p 20
###xml 65 67 65 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 85 91 <span type="species:ncbi:9986">rabbit</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 215 220 <span type="species:ncbi:10090">mouse</span>
###xml 355 360 <span type="species:ncbi:10090">mouse</span>
###xml 487 492 <span type="species:ncbi:10090">mouse</span>
Western blots were prepared essentially as previously described (50). The polyclonal rabbit anti-human S100A2 serum was used in a 1 : 100 dilution. The blot was stripped and reprobed with a 1 : 5000 dilution of the mouse monoclonal anti-beta-actin antibody (clone AC-15, Sigma, Taufkirchen, Germany). The induction of p53 was detected with the monoclonal mouse antibody DO-1 (Calbiochem, Darmstadt, Germany; 1 : 5000 dilution), whereas the induction of TAp63gamma was detected using the mouse monoclonal anti-p63 antibody (clone 4A4; sc-8431 Santa Cruz Biotechnology, Santa Cruz, CA, USA) with a 1 : 250 dilution.
###end p 20
###begin title 21
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 50 53 50 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63</italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
Cloning and mutation of human S100A2 promoter and p63 expression constructs
###end title 21
###begin p 22
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 284 290 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 14 19 <span type="species:ncbi:9606">human</span>
The wild-type human S100A2-promoter firefly-luciferase construct S100A2 short (20) was kindly provided by Dr Beat W. Schafer (University of Zurich, Switzerland). However, most experiments were performed with a newly created longer promoter construct. To this end, the first intron of S100A2 was amplified using the primers 5'-TTT GGT ACC GCC CCA GGT TGC TTC TCT C-3' and 5'-TTT AGA TCT TGG ATC TGT GGC TGC AGA G-3'. This fragment was cloned into the KpnI/BgIII sites of pGI3 basic vector (Promega, Mannheim, Germany). In order to obtain the S100A2 long luciferase construct the intron 1 fragment was cut out by SfiI/BgIII and inserted into the S100A2 short promoter in pGI3 that had been linearized by SfiI/HindIII digestion (GenBank accession number EU036993). Promoter mutants were created by PCR-based targeted mutagenesis on the basis of S100A2 long employing the primers site1-5'mut-fwd, 5'-GGA TAG AGG GTG CAG GCA TGT GTG GGT CGA TTC TGA AC-3'; site1-3'mut-fwd, 5'-TAG AGG GCA TGG GTC GAT GTG GGT CGA TTC TGA AC-3'; site2-mut1-fwd, 5'-GGA TT GGA TTG AGG TGG ATT TGG TTT CC-3'; site2-mut2-fwd, 5'-GGA TCA TGT TGA GGC ATG TTT GGT TTC C-3'; and the respective reverse primers.
###end p 22
###begin p 23
###xml 202 204 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 732 734 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
TAp63gamma mutants were created by PCR-based targeted mutagenesis using the QuikChange (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol on the basis of TAp63gamma-pcDNA3.1/HisC (44) employing the primers TAp63gamma-K193E-fwd, 5'-GCC ATG CCT GTC TAC GAA AAA GCT GAG CAC GTC AC-3'; TAp63gamma-K194E-fwd, 5'-CAT GCC TGT CTA CAA AGA AGC TGA GCA CGT CAC GG-3'; TAp63gamma-R204W-fwd 5'-GGA GGT GGT GAA GTG GTG CCC CAA CCA TG-3'; TAp63gamma-R279H-fwd, 5'-GTT GTG TTG GAG GGA TGA ACC ACC GTC CAA TTT TAA TCA TTG-3'; TAp63gamma-R298Q-fwd, 5'-CAA GTC CTG GGC CAA CGC TGC TTT GAG GC-3'; and the respective reverse primers. Identity of constructs was confirmed by DNA sequencing. TAp63gamma-R304H was published earlier (44).
###end p 23
###begin title 24
Electrophoretic mobility shift assay (EMSA)
###end title 24
###begin p 25
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 94 98 <span type="species:ncbi:9925">goat</span>
###xml 222 227 <span type="species:ncbi:10090">mouse</span>
EMSAs were carried out as previously described (53). TAp63gamma was supershifted by using the goat polyclonal anti-p63gamma antibody (C-18, sc-8370, Santa Cruz Biotechnology) whereas p53 was shifted by adding a monoclonal mouse anti-p53 antibody (pAb421, SA-293, Biomol, Hamburg, Germany). Probes were generated by annealing the following oligonucleotides with respective reverse oligonucleotides: S100A2 site2, fwd 5'-GGG TGG GAT CAG GTT GAG GCA GGT TTG GTT TCC TT-3'; S100A2 site2 mut-1 fwd, 5'-GGG TGG GAT TGG ATT GAG GTG GAT TTG GTT TCC TT-3'; S100A2 site2 mut-2 fwd, 5'-GGG TGG GAT CAT GTT GAG GCA TGT TTG GTT TCC TT-3'; p21 fwd, 5'-GGC CAT CAG GAA CAT GTC CCA ACA TGT TGA GCT CT-3'; mdm2 fwd, 5'-GGG CGG CCG CTG GTC AAG TTG GGA CAC GTC CGG-3'.
###end p 25
###begin title 26
Chromatin immunoprecipitation (ChIP) assays
###end title 26
###begin p 27
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 129 132 129 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 136 146 136 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;</italic>
###xml 180 182 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 430 432 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 242 246 <span type="species:ncbi:9925">goat</span>
ChIPs were carried out guided by a published procedure (54) using HepG2 cells (49) or DLD-1 colorectal adenocarcinoma cells with p53 or TAp63gamma as tet-off-regulated transgenes (44). Protein crosslinks were precipitated using 5 microg of a goat polyclonal anti-p63gamma (C-18, sc-8370, Santa Cruz Biotechnology) or monoclonal anti-p53 antibody (DO-1, Calbiochem, Darmstadt, Germany). Samples were analyzed as described earlier (52) employing the primers IP-S100A2-site1-fwd, 5'-CAG GAC AGA ACA GGT AGA CAC TGA A-3'; IP-S100A2-site1-rev, 5'-CCT GCT GCT GCG TGT CC-3'; IP-S100A2-site2-fwd, 5'-GGT CCA GGA TGC CCA GTC-3'; and IP-S100A2-site2-rev, 5'-GAA GGA GAG CAA GGC AGC-3'.
###end p 27
###begin title 28
RESULTS
###end title 28
###begin title 29
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Induction of S100A2 expression by members of the p53 family
###end title 29
###begin p 30
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 85 87 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 131 137 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 165 167 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 316 322 312 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 543 545 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 574 580 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 665 764 661 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;, TAp63&#945;, &#916;Np63&#947;, &#916;Np63&#945;, TA*p63&#947;, TA*p63&#945;, TAp73&#945; or p53</italic>
###xml 777 785 737 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 809 815 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 940 946 892 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1034 1040 982 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1067 1075 1015 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1079 1085 1027 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1162 1164 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1167 1176 1115 1124 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1177 1178 1125 1126 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1195 1201 1143 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1396 1399 1344 1347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 1407 1413 1355 1361 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1712 1713 1660 1661 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1711 1713 1659 1661 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C<sub>T</sub></italic>
###xml 1780 1781 1728 1729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1845 1846 1793 1794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1864 1865 1810 1811 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1883 1888 1827 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1931 1932 1875 1876 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2407 2413 2335 2341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1176 2674 1124 2595 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="31">(<bold>A</bold>) Stimulation of <italic>S100A2</italic> mRNA expression after selective induction of p53 family members. In RNA preparations from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the <italic>p53</italic> family <italic>S100A2</italic> mRNA levels were measured. Relative mRNA levels were determined by real-time RT&#8211;PCR and changes in expression are given as induction factor comparing mRNA levels 9 h after tet-off induction to levels before induction. Averages of three experiments including standard deviations are shown. Average <italic>C<sub>T</sub></italic> values are denoted before (no) and after (ind) tet-off induction. <italic>t</italic>-test was carried out to yield statistic significance values (**<italic>P</italic>-value &#8804; 0.01; *<italic>P</italic>-value &#8804; 0.05). <italic>GAPDH</italic> expression was used for standardization. (<bold>B</bold>) Stimulation of S100A2 protein expression after induction of TAp63&#947;. S100A2 protein was analyzed by western blot comparing expression before (n) and 9 h after (i) tet-off regulated p53 or TAp63&#947; expression in the colorectal adenocarcinoma cell line DLD-1. In each lane 60 &#181;g of total cell lysate was loaded. S100A2 protein was detected with polyclonal antibodies raised against full-length human S100A2. Lysates from HCT116 cells (15 &#181;g) transfected with an <italic>S100A2</italic>-expressing plasmid and HaCaT cells (5 &#181;g) served as positive controls. Induction of p53 and p63 expression was analyzed by comparison of cell lysates before (n) and after induction (i) of the transgenes. Detection of &#946;-actin served as a loading control.</p>
###xml 1176 2674 1124 2595 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="31">(<bold>A</bold>) Stimulation of <italic>S100A2</italic> mRNA expression after selective induction of p53 family members. In RNA preparations from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the <italic>p53</italic> family <italic>S100A2</italic> mRNA levels were measured. Relative mRNA levels were determined by real-time RT&#8211;PCR and changes in expression are given as induction factor comparing mRNA levels 9 h after tet-off induction to levels before induction. Averages of three experiments including standard deviations are shown. Average <italic>C<sub>T</sub></italic> values are denoted before (no) and after (ind) tet-off induction. <italic>t</italic>-test was carried out to yield statistic significance values (**<italic>P</italic>-value &#8804; 0.01; *<italic>P</italic>-value &#8804; 0.05). <italic>GAPDH</italic> expression was used for standardization. (<bold>B</bold>) Stimulation of S100A2 protein expression after induction of TAp63&#947;. S100A2 protein was analyzed by western blot comparing expression before (n) and 9 h after (i) tet-off regulated p53 or TAp63&#947; expression in the colorectal adenocarcinoma cell line DLD-1. In each lane 60 &#181;g of total cell lysate was loaded. S100A2 protein was detected with polyclonal antibodies raised against full-length human S100A2. Lysates from HCT116 cells (15 &#181;g) transfected with an <italic>S100A2</italic>-expressing plasmid and HaCaT cells (5 &#181;g) served as positive controls. Induction of p53 and p63 expression was analyzed by comparison of cell lysates before (n) and after induction (i) of the transgenes. Detection of &#946;-actin served as a loading control.</p></caption>
###xml 2674 2674 2595 2595 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f1"/>
###xml 1167 2674 1115 2595 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="31">(<bold>A</bold>) Stimulation of <italic>S100A2</italic> mRNA expression after selective induction of p53 family members. In RNA preparations from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the <italic>p53</italic> family <italic>S100A2</italic> mRNA levels were measured. Relative mRNA levels were determined by real-time RT&#8211;PCR and changes in expression are given as induction factor comparing mRNA levels 9 h after tet-off induction to levels before induction. Averages of three experiments including standard deviations are shown. Average <italic>C<sub>T</sub></italic> values are denoted before (no) and after (ind) tet-off induction. <italic>t</italic>-test was carried out to yield statistic significance values (**<italic>P</italic>-value &#8804; 0.01; *<italic>P</italic>-value &#8804; 0.05). <italic>GAPDH</italic> expression was used for standardization. (<bold>B</bold>) Stimulation of S100A2 protein expression after induction of TAp63&#947;. S100A2 protein was analyzed by western blot comparing expression before (n) and 9 h after (i) tet-off regulated p53 or TAp63&#947; expression in the colorectal adenocarcinoma cell line DLD-1. In each lane 60 &#181;g of total cell lysate was loaded. S100A2 protein was detected with polyclonal antibodies raised against full-length human S100A2. Lysates from HCT116 cells (15 &#181;g) transfected with an <italic>S100A2</italic>-expressing plasmid and HaCaT cells (5 &#181;g) served as positive controls. Induction of p53 and p63 expression was analyzed by comparison of cell lysates before (n) and after induction (i) of the transgenes. Detection of &#946;-actin served as a loading control.</p></caption><graphic xlink:href="gkn132f1"/></fig>
###xml 2335 2340 <span type="species:ncbi:9606">human</span>
S100A2 is a TAp63gamma-target gene identified earlier in a DNA-microarray screening (55). Another report had previously shown that S100A2 can be upregulated by p53 (20). With these two observations as a starting point, we were interested to test how these two and some of the other members of the p53 family control S100A2 expression and which functional implications this may have. We had earlier established a tet-off regulated expression system for the most relevant p63 splice variants using the colorectal adenocarcinoma cell line DLD-1 (44). We analyzed regulation of S100A2 comparing its mRNA expression by real-time RT-PCR before and 9 h after induction of TAp63gamma, TAp63alpha, DeltaNp63gamma, DeltaNp63alpha, TA*p63gamma, TA*p63alpha, TAp73alpha or p53 transgenes (Figure 1A). We find the mRNA of S100A2 upregulated after induction of p53, TAp73alpha as well as TAp63gamma proteins. The other p53 family proteins did not affect S100A2 expression significantly. Overexpression of TAp63gamma results in a strong increase of S100A2 mRNA up to about 22-fold (Figure 1A). S100A2 induction by p53 is consistent with a previous report by Tan and coworkers (20). Figure 1.(A) Stimulation of S100A2 mRNA expression after selective induction of p53 family members. In RNA preparations from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family S100A2 mRNA levels were measured. Relative mRNA levels were determined by real-time RT-PCR and changes in expression are given as induction factor comparing mRNA levels 9 h after tet-off induction to levels before induction. Averages of three experiments including standard deviations are shown. Average CT values are denoted before (no) and after (ind) tet-off induction. t-test was carried out to yield statistic significance values (**P-value </= 0.01; *P-value </= 0.05). GAPDH expression was used for standardization. (B) Stimulation of S100A2 protein expression after induction of TAp63gamma. S100A2 protein was analyzed by western blot comparing expression before (n) and 9 h after (i) tet-off regulated p53 or TAp63gamma expression in the colorectal adenocarcinoma cell line DLD-1. In each lane 60 microg of total cell lysate was loaded. S100A2 protein was detected with polyclonal antibodies raised against full-length human S100A2. Lysates from HCT116 cells (15 microg) transfected with an S100A2-expressing plasmid and HaCaT cells (5 microg) served as positive controls. Induction of p53 and p63 expression was analyzed by comparison of cell lysates before (n) and after induction (i) of the transgenes. Detection of beta-actin served as a loading control.
###end p 30
###begin p 31
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 19 25 19 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 231 237 231 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 536 537 536 537 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 535 537 535 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C<sub>T</sub></italic>
###xml 604 605 604 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 669 670 669 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 688 689 686 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 707 712 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 755 756 751 752 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1231 1237 1211 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1159 1164 <span type="species:ncbi:9606">human</span>
(A) Stimulation of S100A2 mRNA expression after selective induction of p53 family members. In RNA preparations from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family S100A2 mRNA levels were measured. Relative mRNA levels were determined by real-time RT-PCR and changes in expression are given as induction factor comparing mRNA levels 9 h after tet-off induction to levels before induction. Averages of three experiments including standard deviations are shown. Average CT values are denoted before (no) and after (ind) tet-off induction. t-test was carried out to yield statistic significance values (**P-value </= 0.01; *P-value </= 0.05). GAPDH expression was used for standardization. (B) Stimulation of S100A2 protein expression after induction of TAp63gamma. S100A2 protein was analyzed by western blot comparing expression before (n) and 9 h after (i) tet-off regulated p53 or TAp63gamma expression in the colorectal adenocarcinoma cell line DLD-1. In each lane 60 microg of total cell lysate was loaded. S100A2 protein was detected with polyclonal antibodies raised against full-length human S100A2. Lysates from HCT116 cells (15 microg) transfected with an S100A2-expressing plasmid and HaCaT cells (5 microg) served as positive controls. Induction of p53 and p63 expression was analyzed by comparison of cell lysates before (n) and after induction (i) of the transgenes. Detection of beta-actin served as a loading control.
###end p 31
###begin p 32
###xml 347 348 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 407 413 407 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 466 474 466 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 731 739 727 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 220 225 <span type="species:ncbi:9606">human</span>
###xml 275 280 <span type="species:ncbi:9606">human</span>
###xml 355 360 <span type="species:ncbi:9606">human</span>
More important for S100A2 function is an induction on the protein level. Since a number of commercially available antibodies were not of sufficient sensitivity, we generated polyclonal antibodies against the full-length human S100A2 protein. S100A2 protein was detected from human HaCaT keratinocytes, known to express high levels of the protein (3), and human colon cancer HCT116 cells transfected with an S100A2 expression plasmid as controls by western analysis (Figure 1B). Employing this antibody preparation, we tested S100A2 expression comparing the protein level before and 9 h after induction of the respective transgene in the DLD-1-system. A clear induction of S100A2 was observed following the induction of TAp63gamma (Figure 1B). However, no S100A2 protein was detectable after induction of p53 despite a clear increase in p53 protein expression. Taken together with the observations on the mRNA level, this finding indicates that S100A2 protein expression induced by TAp63gamma is stronger than the induction by p53.
###end p 32
###begin title 33
###xml 42 48 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
TAp63gamma regulates transcription of the S100A2 gene
###end title 33
###begin p 34
###xml 72 78 68 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 213 219 209 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 375 377 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 421 429 417 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 490 493 486 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 498 508 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;</italic>
###xml 696 704 684 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 829 835 817 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1104 1112 1092 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1313 1321 1297 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1325 1334 1309 1318 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1354 1360 1338 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1469 1470 1449 1450 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1520 1526 1500 1506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1679 1680 1655 1656 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2081 2088 2045 2052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 2278 2279 2242 2243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2767 2768 2715 2716 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2877 2883 2821 2827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 2939 2940 2883 2884 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2961 2967 2905 2911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 3065 3072 3009 3016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63/p73</italic>
###xml 1334 3302 1318 3246 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="35">A novel site in the <italic>S100A2</italic> promoter different from a previously recognized element mediates transcriptional activation by TAp63&#947;. (<bold>A</bold>) Structure of the analyzed promoter fragments of <italic>S100A2</italic> upstream of the translational start containing previously published p53 element (site 1) and the newly identified TAp63&#947;-binding element (site 2). (<bold>B</bold>) The S100A2 short-reporter is activated by increasing amounts of TAp63&#947; but not by p53 or DNA binding-deficient mutants of TAp63&#947; or p53. In SaOS-2 cells 250 ng of the S100A2 short plasmid were cotransfected with increasing amounts starting with 2 ng up to 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. All experiments were standardized to <italic>Renilla</italic> luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held constant. Averages from four experiments with standard deviations are given. (<bold>C</bold>) The S100A2 long reporter is activated by TAp63&#947; and to a lesser extent by p53 but not by DNA binding-deficient mutants of TAp63&#947; and p53. Mutation of site 1 abrogates p53-mediated but not TAp63&#947;-mediated transactivation. In SaOS-2 cells, 400 ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. Standardization was done as described above. (<bold>D</bold>) Mutations of the novel consensus element (site 2) influence TAp63&#947;- and p53-mediated activation of the <italic>S100A2</italic> promoter. Transfections were done as described above. (<bold>E</bold>) Transactivation of <italic>S100A2</italic> by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing <italic>p63/p73</italic> family members or their DNA-binding deficient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter activities from three independent experiments with standard deviations are shown.</p>
###xml 1334 3302 1318 3246 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="35">A novel site in the <italic>S100A2</italic> promoter different from a previously recognized element mediates transcriptional activation by TAp63&#947;. (<bold>A</bold>) Structure of the analyzed promoter fragments of <italic>S100A2</italic> upstream of the translational start containing previously published p53 element (site 1) and the newly identified TAp63&#947;-binding element (site 2). (<bold>B</bold>) The S100A2 short-reporter is activated by increasing amounts of TAp63&#947; but not by p53 or DNA binding-deficient mutants of TAp63&#947; or p53. In SaOS-2 cells 250 ng of the S100A2 short plasmid were cotransfected with increasing amounts starting with 2 ng up to 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. All experiments were standardized to <italic>Renilla</italic> luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held constant. Averages from four experiments with standard deviations are given. (<bold>C</bold>) The S100A2 long reporter is activated by TAp63&#947; and to a lesser extent by p53 but not by DNA binding-deficient mutants of TAp63&#947; and p53. Mutation of site 1 abrogates p53-mediated but not TAp63&#947;-mediated transactivation. In SaOS-2 cells, 400 ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. Standardization was done as described above. (<bold>D</bold>) Mutations of the novel consensus element (site 2) influence TAp63&#947;- and p53-mediated activation of the <italic>S100A2</italic> promoter. Transfections were done as described above. (<bold>E</bold>) Transactivation of <italic>S100A2</italic> by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing <italic>p63/p73</italic> family members or their DNA-binding deficient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter activities from three independent experiments with standard deviations are shown.</p></caption>
###xml 3302 3302 3246 3246 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f2a"/>
###xml 3302 3302 3246 3246 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f2b"/>
###xml 1325 3302 1309 3246 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="35">A novel site in the <italic>S100A2</italic> promoter different from a previously recognized element mediates transcriptional activation by TAp63&#947;. (<bold>A</bold>) Structure of the analyzed promoter fragments of <italic>S100A2</italic> upstream of the translational start containing previously published p53 element (site 1) and the newly identified TAp63&#947;-binding element (site 2). (<bold>B</bold>) The S100A2 short-reporter is activated by increasing amounts of TAp63&#947; but not by p53 or DNA binding-deficient mutants of TAp63&#947; or p53. In SaOS-2 cells 250 ng of the S100A2 short plasmid were cotransfected with increasing amounts starting with 2 ng up to 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. All experiments were standardized to <italic>Renilla</italic> luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held constant. Averages from four experiments with standard deviations are given. (<bold>C</bold>) The S100A2 long reporter is activated by TAp63&#947; and to a lesser extent by p53 but not by DNA binding-deficient mutants of TAp63&#947; and p53. Mutation of site 1 abrogates p53-mediated but not TAp63&#947;-mediated transactivation. In SaOS-2 cells, 400 ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63&#947; or p53. Standardization was done as described above. (<bold>D</bold>) Mutations of the novel consensus element (site 2) influence TAp63&#947;- and p53-mediated activation of the <italic>S100A2</italic> promoter. Transfections were done as described above. (<bold>E</bold>) Transactivation of <italic>S100A2</italic> by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing <italic>p63/p73</italic> family members or their DNA-binding deficient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter activities from three independent experiments with standard deviations are shown.</p></caption><graphic xlink:href="gkn132f2a"/><graphic xlink:href="gkn132f2b"/></fig>
After finding that increased expression of TAp63gamma leads to elevated S100A2 mRNA and protein levels, we tested if this regulation is controlled on the transcriptional level. Initially, we used in our assays an S100A2-promoter fragment-reporter construct which was kindly provided by Dr Beat W. Schafer (University of Zurich) and had been published to be regulated by p53 (20). This construct, designated S100A2 short (Figure 2A), was transfected into SaOS-2 cells. Increasing amounts of p53- or TAp63gamma-expressing plasmids were cotransfected. As controls, their DNA binding-deficient mutants were also assayed. Wild-type TAp63gamma was able to activate the promoter fragment about 16-fold (Figure 2B). Surprisingly, p53 was not able to induce expression from the S100A2 short construct, leaving the question unanswered why S100A2 mRNA increases after p53 induction. Trying to explain this discrepancy we extended the S100A2 short promoter by a fragment of about 2 kb up to the translational start creating S100A2 long. This reporter construct includes the untranslated exon 1 and the first intron (Figure 2A). Activation by p53 of this promoter results in an increase of about 3.5-fold. Much more substantial is the activation by TAp63gamma which enhances the expression of the reporter gene about 43-fold (Figure 2C). Figure 2.A novel site in the S100A2 promoter different from a previously recognized element mediates transcriptional activation by TAp63gamma. (A) Structure of the analyzed promoter fragments of S100A2 upstream of the translational start containing previously published p53 element (site 1) and the newly identified TAp63gamma-binding element (site 2). (B) The S100A2 short-reporter is activated by increasing amounts of TAp63gamma but not by p53 or DNA binding-deficient mutants of TAp63gamma or p53. In SaOS-2 cells 250 ng of the S100A2 short plasmid were cotransfected with increasing amounts starting with 2 ng up to 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63gamma or p53. All experiments were standardized to Renilla luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held constant. Averages from four experiments with standard deviations are given. (C) The S100A2 long reporter is activated by TAp63gamma and to a lesser extent by p53 but not by DNA binding-deficient mutants of TAp63gamma and p53. Mutation of site 1 abrogates p53-mediated but not TAp63gamma-mediated transactivation. In SaOS-2 cells, 400 ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63gamma or p53. Standardization was done as described above. (D) Mutations of the novel consensus element (site 2) influence TAp63gamma- and p53-mediated activation of the S100A2 promoter. Transfections were done as described above. (E) Transactivation of S100A2 by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing p63/p73 family members or their DNA-binding deficient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter activities from three independent experiments with standard deviations are shown.
###end p 34
###begin p 35
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 135 136 131 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 186 192 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 345 346 337 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 747 754 727 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 944 945 924 925 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1433 1434 1397 1398 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1543 1549 1503 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1605 1606 1565 1566 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1627 1633 1587 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1731 1738 1691 1698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63/p73</italic>
A novel site in the S100A2 promoter different from a previously recognized element mediates transcriptional activation by TAp63gamma. (A) Structure of the analyzed promoter fragments of S100A2 upstream of the translational start containing previously published p53 element (site 1) and the newly identified TAp63gamma-binding element (site 2). (B) The S100A2 short-reporter is activated by increasing amounts of TAp63gamma but not by p53 or DNA binding-deficient mutants of TAp63gamma or p53. In SaOS-2 cells 250 ng of the S100A2 short plasmid were cotransfected with increasing amounts starting with 2 ng up to 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63gamma or p53. All experiments were standardized to Renilla luciferase activity expressed from cotransfected pRL-null vector. The total amount of DNA transfected was held constant. Averages from four experiments with standard deviations are given. (C) The S100A2 long reporter is activated by TAp63gamma and to a lesser extent by p53 but not by DNA binding-deficient mutants of TAp63gamma and p53. Mutation of site 1 abrogates p53-mediated but not TAp63gamma-mediated transactivation. In SaOS-2 cells, 400 ng reporter plasmid containing wild-type or mutated S100A2 long were cotransfected with 25 ng of the plasmids expressing wild-type or DNA binding-deficient mutants of TAp63gamma or p53. Standardization was done as described above. (D) Mutations of the novel consensus element (site 2) influence TAp63gamma- and p53-mediated activation of the S100A2 promoter. Transfections were done as described above. (E) Transactivation of S100A2 by several members of the p63/p73 family is mediated by the novel element 2. Plasmids expressing p63/p73 family members or their DNA-binding deficient mutants were transfected with the S100A2 long reporter construct in SaOS-2 cells. Luciferase reporter activities from three independent experiments with standard deviations are shown.
###end p 35
###begin p 36
###xml 278 284 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 286 294 271 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 395 401 380 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Furthermore, we analyzed the influence of other p63/p73 splice variants in the same assay. We find a strong activation of the reporter by expressing TAp73beta which was not tested in our previous approaches. Also TAp73alpha, TA*p63gamma and TA*p63alpha enhance transcription of S100A2 (Figure 2E). The other p53 family proteins tested only have a minor role in transcriptional activation of the S100A2 promoter.
###end p 36
###begin p 37
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
In summary, p53 is able to activate transcription of S100A2. However, p63 and p73 proteins appear to be more potent activators of S100A2 transcription.
###end p 37
###begin title 38
###xml 69 75 65 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
A novel response element mediates TAp63gamma-dependent regulation of S100A2
###end title 38
###begin p 39
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 233 235 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 359 368 355 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 610 618 602 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 677 683 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 910 916 894 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1193 1195 1177 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 1255 1261 1239 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1803 1811 1787 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1843 1849 1827 1833 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 2012 2018 1988 1994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 2029 2037 2005 2013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2238 2246 2214 2222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2327 2333 2303 2309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 2393 2401 2369 2377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 2527 2533 2503 2509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
In order to determine the responding element mediating S100A2 transcription by strong activators like TAp63gamma we created some promoter mutants in sites similar to the p53 consensus (). Initially the described p53-binding element (20) designated here as site 1 () was tested. In addition to this potential p53-binding site, referred to as S100A2 site 1-3', in silico analyses revealed an additional potential consensus in this region, denoted as S100A2 site 1-5'. Mutation of these elements results in a loss of the p53-dependent activation whereas TAp63gamma is still able to activate this promoter mutant (Figure 2C). We narrowed down the TAp63gamma-responsive part of the S100A2 promoter by creating and testing several deletion mutants. A region of about 80-bp upstream from the untranslated exon 1 was identified to be required for TAp63gamma-mediated transcription (data not shown). Comparison of this S100A2 promoter segment to the known p53-consensus sequence revealed a potential binding element consisting of two consecutive palindromes lacking any spacer region (). This element, designated site 2, contains 4 bp which are different from the classical p53 consensus (RRRCWWGYYY) (56). Instead of the established core-binding element CWWG the S100A2 promoter shows the nucleotide sequence CAGG in each half of the palindrome. Furthermore, next to the core another 2 bp are changed in the upstream palindrome in comparison to the consensus (). Moreover, phylogenetical footprint analyses reveal a strong conservation of this site within vertebrates (data not shown), implying a possible function for this region. To test functional importance of site 2 we mutated this element in a way that the core of the site was destroyed and used the resulting reporter in transient transfection assays (Figure 2D, site 2 mut-1). Activation of S100A2 transcription by TAp63gamma is essentially lost upon mutation of site 2, identifying this element as the major site for TAp63gamma-dependent transcription in the S100A2 promoter (Figure 2D). When this mutant was tested with other proteins of the p63/p73 family, we observed that the newly identified site 2 appears to be essential also for transactivation by these other splice variants (Figure 2E, site 2 mut-1). In contrast, mutation of site 1 affects transactivation of the S100A2 reporter by p63/p73 family members only to a minor extent (Figure 2E, site 1-3' mut), emphasizing the importance of the newly identified element 2 for mediating p63/p73-dependent regulation of S100A2.
###end p 39
###begin p 40
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 205 211 201 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 327 335 323 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
In another mutant, a bona fide p53 consensus was created by changing the guanine in position three to a thymidine in the core-binding element CAGG of site 2 (). TAp63gamma was able to activate this mutant S100A2 promoter clearly. Furthermore, this promoter construct shows a significant induction also after expression of p53 (Figure 2D, site 2 mut-2). Changing just this single base in each half of the palindrome appears sufficient to alter a site preferentially bound by p63 and p73 proteins into a functional p53 element.
###end p 40
###begin p 41
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Taken together, we have identified a novel promoter element which is different from the established p53 consensus mediating S100A2 transactivation selectively by p63/p73 proteins.
###end p 41
###begin title 42
###xml 41 47 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 65 73 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
TAp63gamma, but not p53, binds the novel S100A2 promoter element in vitro
###end title 42
###begin p 43
###xml 43 49 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 123 131 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 182 191 178 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 179 191 175 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>WAF1/CIP1</sup></italic>
###xml 386 394 378 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 463 469 451 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 608 610 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 690 698 678 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 800 809 784 793 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 849 855 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 883 891 863 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1001 1009 977 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1068 1077 1044 1053 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1065 1077 1041 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>WAF1/CIP1</sup></italic>
###xml 1136 1142 1112 1118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1292 1293 1264 1265 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1344 1353 1312 1321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 1341 1353 1309 1321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>WAF1/CIP1</sup></italic>
###xml 1370 1376 1338 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1405 1406 1373 1374 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1441 1447 1405 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1536 1537 1500 1501 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1576 1580 1540 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdm2</italic>
###xml 809 1745 793 1709 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="44">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vitro</italic>, whereas no binding of p53 is detectable. Wild-type or mutant TAp63&#947; or p53 were produced by translation <italic>in vitro</italic> and incubated with probes representing a p53 site from <italic>p21<sup>WAF1/CIP1</sup></italic> promoter as positive control or the novel site 2 from the <italic>S100A2</italic> promoter. In some samples, specificity of detected binding was verified by adding antibody against p63&#947; or p53. Samples were analyzed in EMSAs. (<bold>A</bold>) Binding of TAp63&#947; respectively p53 to the <italic>p21<sup>WAF1/CIP1</sup></italic> probe or to the <italic>S100A2</italic> promoter wild-type site 2. (<bold>B</bold>) TAp63&#947; or p53 binding to the <italic>S100A2</italic> promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2 site 2 mut-2. (<bold>C</bold>) A probe carrying a p53 site from the <italic>mdm2</italic> promoter was employed in EMSAs. Binding to the labeled probe was competed with a 100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.</p>
###xml 809 1745 793 1709 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="44">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vitro</italic>, whereas no binding of p53 is detectable. Wild-type or mutant TAp63&#947; or p53 were produced by translation <italic>in vitro</italic> and incubated with probes representing a p53 site from <italic>p21<sup>WAF1/CIP1</sup></italic> promoter as positive control or the novel site 2 from the <italic>S100A2</italic> promoter. In some samples, specificity of detected binding was verified by adding antibody against p63&#947; or p53. Samples were analyzed in EMSAs. (<bold>A</bold>) Binding of TAp63&#947; respectively p53 to the <italic>p21<sup>WAF1/CIP1</sup></italic> probe or to the <italic>S100A2</italic> promoter wild-type site 2. (<bold>B</bold>) TAp63&#947; or p53 binding to the <italic>S100A2</italic> promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2 site 2 mut-2. (<bold>C</bold>) A probe carrying a p53 site from the <italic>mdm2</italic> promoter was employed in EMSAs. Binding to the labeled probe was competed with a 100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.</p></caption>
###xml 1745 1745 1709 1709 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f3"/>
###xml 800 1745 784 1709 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="44">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vitro</italic>, whereas no binding of p53 is detectable. Wild-type or mutant TAp63&#947; or p53 were produced by translation <italic>in vitro</italic> and incubated with probes representing a p53 site from <italic>p21<sup>WAF1/CIP1</sup></italic> promoter as positive control or the novel site 2 from the <italic>S100A2</italic> promoter. In some samples, specificity of detected binding was verified by adding antibody against p63&#947; or p53. Samples were analyzed in EMSAs. (<bold>A</bold>) Binding of TAp63&#947; respectively p53 to the <italic>p21<sup>WAF1/CIP1</sup></italic> probe or to the <italic>S100A2</italic> promoter wild-type site 2. (<bold>B</bold>) TAp63&#947; or p53 binding to the <italic>S100A2</italic> promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2 site 2 mut-2. (<bold>C</bold>) A probe carrying a p53 site from the <italic>mdm2</italic> promoter was employed in EMSAs. Binding to the labeled probe was competed with a 100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.</p></caption><graphic xlink:href="gkn132f3"/></fig>
Binding of TAp63gamma and p53 to the novel S100A2 promoter element site 2 was tested by EMSA employing proteins translated in vitro. An established p53-consensus element from the p21WAF1/CIP1 promoter was used as a positive control. Both, wild-type TAp63gamma and p53 gave a specific signal for the control element. Addition of antibodies against p53 or p63 led to a supershifted band (Figure 3A). EMSAs yielded binding of TAp63gamma to the site 2 element in the S100A2 promoter. p53 did not show significant binding to this site. Enhancement of p53 binding upon supplementing antibodies had been described (57). However, even addition of antibodies did not yield a detectable p53 binding (Figure 3A). As a negative control, DNA binding-deficient mutants of p53 or TAp63gamma proteins were employed. Figure 3.TAp63gamma is able to bind to the novel S100A2 promoter consensus element in vitro, whereas no binding of p53 is detectable. Wild-type or mutant TAp63gamma or p53 were produced by translation in vitro and incubated with probes representing a p53 site from p21WAF1/CIP1 promoter as positive control or the novel site 2 from the S100A2 promoter. In some samples, specificity of detected binding was verified by adding antibody against p63gamma or p53. Samples were analyzed in EMSAs. (A) Binding of TAp63gamma respectively p53 to the p21WAF1/CIP1 probe or to the S100A2 promoter wild-type site 2. (B) TAp63gamma or p53 binding to the S100A2 promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2 site 2 mut-2. (C) A probe carrying a p53 site from the mdm2 promoter was employed in EMSAs. Binding to the labeled probe was competed with a 100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.
###end p 43
###begin p 44
###xml 40 46 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 74 82 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 192 200 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 259 268 251 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 256 268 248 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>WAF1/CIP1</sup></italic>
###xml 327 333 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 483 484 471 472 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 535 544 519 528 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WAF1/CIP1</sup>
###xml 532 544 516 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21<sup>WAF1/CIP1</sup></italic>
###xml 561 567 545 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 596 597 580 581 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 632 638 612 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 727 728 707 708 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 767 771 747 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdm2</italic>
TAp63gamma is able to bind to the novel S100A2 promoter consensus element in vitro, whereas no binding of p53 is detectable. Wild-type or mutant TAp63gamma or p53 were produced by translation in vitro and incubated with probes representing a p53 site from p21WAF1/CIP1 promoter as positive control or the novel site 2 from the S100A2 promoter. In some samples, specificity of detected binding was verified by adding antibody against p63gamma or p53. Samples were analyzed in EMSAs. (A) Binding of TAp63gamma respectively p53 to the p21WAF1/CIP1 probe or to the S100A2 promoter wild-type site 2. (B) TAp63gamma or p53 binding to the S100A2 promoter wild-type site 2 or two mutants, S100A2 site 2 mut-1 and S100A2 site 2 mut-2. (C) A probe carrying a p53 site from the mdm2 promoter was employed in EMSAs. Binding to the labeled probe was competed with a 100-fold excess of unlabelled DNA of wild-type or two mutants of the S100A2 site 2.
###end p 44
###begin p 45
###xml 161 169 157 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 420 428 412 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
Applying a probe representing a mutant of site 2 which does not allow TAp63gamma-dependent transactivation of the reporter binds neither p63 nor p53 in an EMSA (Figure 3B, S100A2 site 2 mut-1). However, using a mutant-2 probe containing the restored p53 consensus results in an enhanced binding of wild-type TAp63gamma. Consistent with our data from the reporter assays we also find binding of p53 to this DNA fragment (Figure 3B, S100A2 site 2 mut-2).
###end p 45
###begin p 46
###xml 41 47 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 147 151 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdm2</italic>
###xml 170 178 166 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 263 269 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 478 482 470 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mdm2</italic>
###xml 490 498 482 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
Furthermore, in competition experiments, S100A2 wild-type oligonucleotide is able to attenuate the binding of TAp63gamma to a probe containing the mdm2 p53-binding site (Figure 3C S100A2 site 2). To a lesser extent, also binding of p53 to mdm2 is reduced. Mutant S100A2 oligonucleotide (S100A2 site 2 mut-1) failed to diminish these interactions, whereas oligonucleotides containing the restored p53 consensus (S100A2 site 2 mut-2) prevented binding of TAp63gamma or p53 to the mdm2 probe (Figure 3C).
###end p 46
###begin p 47
###xml 78 84 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 102 110 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
In conclusion, we showed a sequence-specific binding of TAp63gamma to a novel S100A2 promoter element in vitro, whereas p53 was not able to bind this fragment. Changing one base in each half of the palindrome in order to create a classical p53 consensus sequence resulted in an enhanced binding by TAp63gamma and a clear detectable interaction also with p53.
###end p 47
###begin title 48
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 45 51 41 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
In vivo binding of TAp63gamma and p53 to the S100A2 promoter
###end title 48
###begin p 49
###xml 55 61 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 79 86 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 234 240 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 342 348 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 358 365 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 367 375 355 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 378 387 366 375 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 427 433 411 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 461 468 445 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 769 775 745 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 980 981 956 957 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 387 1003 375 979 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="50">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vivo</italic>. Chromatin from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family were cross-linked before (uninduced) and 9 h after induction (induced) of TAp63&#947; or p53 expression. After precipitation with antibodies against p63&#947; or p53, the <italic>S100A2</italic> promoter regions containing the p53 element published earlier (site 1) or the novel element (site 2) were amplified by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water control (H<sub>2</sub>O) and DNA ladder (M).</p>
###xml 387 1003 375 979 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="50">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vivo</italic>. Chromatin from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family were cross-linked before (uninduced) and 9 h after induction (induced) of TAp63&#947; or p53 expression. After precipitation with antibodies against p63&#947; or p53, the <italic>S100A2</italic> promoter regions containing the p53 element published earlier (site 1) or the novel element (site 2) were amplified by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water control (H<sub>2</sub>O) and DNA ladder (M).</p></caption>
###xml 1003 1003 979 979 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f4"/>
###xml 378 1003 366 979 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="50">TAp63&#947; is able to bind to the novel <italic>S100A2</italic> promoter consensus element <italic>in vivo</italic>. Chromatin from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family were cross-linked before (uninduced) and 9 h after induction (induced) of TAp63&#947; or p53 expression. After precipitation with antibodies against p63&#947; or p53, the <italic>S100A2</italic> promoter regions containing the p53 element published earlier (site 1) or the novel element (site 2) were amplified by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water control (H<sub>2</sub>O) and DNA ladder (M).</p></caption><graphic xlink:href="gkn132f4"/></fig>
To test for binding of TAp63gamma protein to the novel S100A2 promoter element in vivo we carried out ChIP analyses. Employing DLD-1 cells carrying a tet-off-regulated system expressing TAp63gamma or p53 binding to two regions of the S100A2 promoter including binding site 1 or site 2 was tested. TAp63gamma and p53 were shown to bind to the S100A2 promoter in vivo (Figure 4). Figure 4.TAp63gamma is able to bind to the novel S100A2 promoter consensus element in vivo. Chromatin from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family were cross-linked before (uninduced) and 9 h after induction (induced) of TAp63gamma or p53 expression. After precipitation with antibodies against p63gamma or p53, the S100A2 promoter regions containing the p53 element published earlier (site 1) or the novel element (site 2) were amplified by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water control (H2O) and DNA ladder (M).
###end p 49
###begin p 50
###xml 40 46 36 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 74 81 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 382 388 370 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 593 594 581 582 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
TAp63gamma is able to bind to the novel S100A2 promoter consensus element in vivo. Chromatin from DLD-1 colorectal adenocarcinoma cells stably transfected with tet-off vectors expressing members of the p53 family were cross-linked before (uninduced) and 9 h after induction (induced) of TAp63gamma or p53 expression. After precipitation with antibodies against p63gamma or p53, the S100A2 promoter regions containing the p53 element published earlier (site 1) or the novel element (site 2) were amplified by PCR from the precipitated DNA. Lanes are input (i), no antibody (n), water control (H2O) and DNA ladder (M).
###end p 50
###begin title 51
###xml 66 72 62 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
EEC syndrome-specific mutants of TAp63gamma fail to transactivate S100A2
###end title 51
###begin p 52
###xml 20 26 20 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 719 725 719 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 823 831 823 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1054 1060 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1137 1143 1137 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1236 1242 1236 1242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1258 1266 1258 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1269 1278 1269 1278 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 1401 1407 1397 1403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1278 1622 1278 1614 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="53">TAp63&#947; mutants related to SHFM, EEC and ADULT human developmental syndromes show a functional difference in regulating <italic>S100A2</italic> transcription. TAp63&#947; mutants originating from patients with developmental syndromes SHFM, EEC or ADULT differentially activate the S100A2 long reporter. Transfections and analyses were done as described above.</p>
###xml 1278 1622 1278 1614 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="53">TAp63&#947; mutants related to SHFM, EEC and ADULT human developmental syndromes show a functional difference in regulating <italic>S100A2</italic> transcription. TAp63&#947; mutants originating from patients with developmental syndromes SHFM, EEC or ADULT differentially activate the S100A2 long reporter. Transfections and analyses were done as described above.</p></caption>
###xml 1622 1622 1614 1614 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f5"/>
###xml 1269 1622 1269 1614 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="53">TAp63&#947; mutants related to SHFM, EEC and ADULT human developmental syndromes show a functional difference in regulating <italic>S100A2</italic> transcription. TAp63&#947; mutants originating from patients with developmental syndromes SHFM, EEC or ADULT differentially activate the S100A2 long reporter. Transfections and analyses were done as described above.</p></caption><graphic xlink:href="gkn132f5"/></fig>
###xml 121 126 <span type="species:ncbi:9606">human</span>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 463 469 <span type="species:ncbi:9606">people</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
###xml 1105 1113 <span type="species:ncbi:9606">patients</span>
###xml 1328 1333 <span type="species:ncbi:9606">human</span>
###xml 1459 1467 <span type="species:ncbi:9606">patients</span>
Since we found that S100A2 expression is regulated by p63 we were interested to test mutants of this protein relevant in human syndromes for their properties. Mutations such as R204, R279 and R304 found in EEC patients correspond to hotspot mutations in the DNA-binding domain of p53 observed in cancer (58). Unlike to those mutants, p63 mutations responsible for the SHFM phenotype such as K193 or K194 do not directly participate in DNA binding. In contrast to people suffering from EEC syndrome, SHFM patients do not exhibit ectodermal dysplasia and facial cleftings, which are also found in individuals with the ADULT syndrome. Several syndrome-derived p63 mutants were assayed as transcriptional activators of the S100A2 promoter: EEC syndrome, R204W, R279H, R304A; SHFM syndrome, K193E, K194E; ADULT syndrome, R298Q (Figure 5). As a control, p63 mutant proteins were tested for comparable expression by western analysis (data not shown). The reporter assays indicate that EEC syndrome-derived mutants are not able to transactivate transcription of S100A2. In contrast, p63 mutants derived from SHFM patients even appear to enhance S100A2 reporter activity. Mutations related to the ADULT syndrome are still able to stimulate some S100A2 transcription (Figure 5). Figure 5.TAp63gamma mutants related to SHFM, EEC and ADULT human developmental syndromes show a functional difference in regulating S100A2 transcription. TAp63gamma mutants originating from patients with developmental syndromes SHFM, EEC or ADULT differentially activate the S100A2 long reporter. Transfections and analyses were done as described above.
###end p 52
###begin p 53
###xml 123 129 119 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 50 55 <span type="species:ncbi:9606">human</span>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
TAp63gamma mutants related to SHFM, EEC and ADULT human developmental syndromes show a functional difference in regulating S100A2 transcription. TAp63gamma mutants originating from patients with developmental syndromes SHFM, EEC or ADULT differentially activate the S100A2 long reporter. Transfections and analyses were done as described above.
###end p 53
###begin title 54
###xml 35 41 31 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 67 73 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Binding of p63gamma protein to the S100A2 promoter correlates with S100A2 expression after DNA damage
###end title 54
###begin p 55
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 97 103 97 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63</italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 305 310 305 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 492 500 492 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 535 544 535 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Np63</italic>
###xml 549 554 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp73</italic>
###xml 630 639 626 635 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 678 684 670 676 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 706 712 698 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 740 741 732 733 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 743 753 735 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;</italic>
###xml 758 764 746 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 841 847 829 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 852 857 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 956 961 944 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1097 1098 1085 1086 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1389 1390 1374 1375 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1406 1412 1391 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1449 1454 1434 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1596 1601 1581 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 1630 1636 1615 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1710 1715 1695 1700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1752 1757 1737 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1820 1821 1805 1806 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1911 1917 1892 1898 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 639 2102 635 2079 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="56">Recruitment of p63&#947; protein to the <italic>S100A2</italic> promoter may connect <italic>S100A2</italic> expression to DNA damage. (<bold>A</bold>) <italic>TAp63&#947;</italic> and <italic>S100A2</italic> mRNA expression increase after DNA damage. Real-time RT&#8211;PCR measurements of <italic>S100A2</italic> and <italic>TAp63</italic> mRNAs from doxorubicin-treated HepG2 cells. Relative mRNA levels were normalized to expression of <italic>GAPDH</italic> mRNA. Cells before treatment were employed as control. Control levels were set to 100%. Times of doxorubicin treatment are indicated. (<bold>B</bold>) Western blot analyses of lysates from p53-positive HepG2 and p53-negative Hep3B cells after doxorubicin-induced DNA damage. Controls contain samples taken before treatment. Doxorubicin-treated samples were analyzed after 24 h or 48 h. Detection of &#946;-actin served as a loading control. (<bold>C</bold>) Expression of <italic>S100A2</italic> mRNA correlates with an increase of <italic>TAp63</italic> mRNA after doxorubicin-induced DNA damage in p53-negative Hep3B cells. Relative mRNA levels were measured by real-time RT&#8211;PCR. Expression of <italic>GAPDH</italic> was used for normalization. <italic>S100A2</italic> mRNA from untreated control cells was set to 100%. In control samples no <italic>TAp63</italic> mRNA was detectable. Therefore, the <italic>TAp63</italic> mRNA measurement at 24 h was employed as the 100% reference. (<bold>D</bold>) Chromatin immunoprecipitation (ChIP) assays of p53 and p63&#947; proteins binding to the <italic>S100A2</italic> promoter in HepG2 cells following DNA damage. Control and doxorubicin-treated cells were prepared as described above. Lanes are input (i), no antibody (n), p53 and p63&#947; antibodies.</p>
###xml 639 2102 635 2079 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="56">Recruitment of p63&#947; protein to the <italic>S100A2</italic> promoter may connect <italic>S100A2</italic> expression to DNA damage. (<bold>A</bold>) <italic>TAp63&#947;</italic> and <italic>S100A2</italic> mRNA expression increase after DNA damage. Real-time RT&#8211;PCR measurements of <italic>S100A2</italic> and <italic>TAp63</italic> mRNAs from doxorubicin-treated HepG2 cells. Relative mRNA levels were normalized to expression of <italic>GAPDH</italic> mRNA. Cells before treatment were employed as control. Control levels were set to 100%. Times of doxorubicin treatment are indicated. (<bold>B</bold>) Western blot analyses of lysates from p53-positive HepG2 and p53-negative Hep3B cells after doxorubicin-induced DNA damage. Controls contain samples taken before treatment. Doxorubicin-treated samples were analyzed after 24 h or 48 h. Detection of &#946;-actin served as a loading control. (<bold>C</bold>) Expression of <italic>S100A2</italic> mRNA correlates with an increase of <italic>TAp63</italic> mRNA after doxorubicin-induced DNA damage in p53-negative Hep3B cells. Relative mRNA levels were measured by real-time RT&#8211;PCR. Expression of <italic>GAPDH</italic> was used for normalization. <italic>S100A2</italic> mRNA from untreated control cells was set to 100%. In control samples no <italic>TAp63</italic> mRNA was detectable. Therefore, the <italic>TAp63</italic> mRNA measurement at 24 h was employed as the 100% reference. (<bold>D</bold>) Chromatin immunoprecipitation (ChIP) assays of p53 and p63&#947; proteins binding to the <italic>S100A2</italic> promoter in HepG2 cells following DNA damage. Control and doxorubicin-treated cells were prepared as described above. Lanes are input (i), no antibody (n), p53 and p63&#947; antibodies.</p></caption>
###xml 2102 2102 2079 2079 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn132f6"/>
###xml 630 2102 626 2079 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="56">Recruitment of p63&#947; protein to the <italic>S100A2</italic> promoter may connect <italic>S100A2</italic> expression to DNA damage. (<bold>A</bold>) <italic>TAp63&#947;</italic> and <italic>S100A2</italic> mRNA expression increase after DNA damage. Real-time RT&#8211;PCR measurements of <italic>S100A2</italic> and <italic>TAp63</italic> mRNAs from doxorubicin-treated HepG2 cells. Relative mRNA levels were normalized to expression of <italic>GAPDH</italic> mRNA. Cells before treatment were employed as control. Control levels were set to 100%. Times of doxorubicin treatment are indicated. (<bold>B</bold>) Western blot analyses of lysates from p53-positive HepG2 and p53-negative Hep3B cells after doxorubicin-induced DNA damage. Controls contain samples taken before treatment. Doxorubicin-treated samples were analyzed after 24 h or 48 h. Detection of &#946;-actin served as a loading control. (<bold>C</bold>) Expression of <italic>S100A2</italic> mRNA correlates with an increase of <italic>TAp63</italic> mRNA after doxorubicin-induced DNA damage in p53-negative Hep3B cells. Relative mRNA levels were measured by real-time RT&#8211;PCR. Expression of <italic>GAPDH</italic> was used for normalization. <italic>S100A2</italic> mRNA from untreated control cells was set to 100%. In control samples no <italic>TAp63</italic> mRNA was detectable. Therefore, the <italic>TAp63</italic> mRNA measurement at 24 h was employed as the 100% reference. (<bold>D</bold>) Chromatin immunoprecipitation (ChIP) assays of p53 and p63&#947; proteins binding to the <italic>S100A2</italic> promoter in HepG2 cells following DNA damage. Control and doxorubicin-treated cells were prepared as described above. Lanes are input (i), no antibody (n), p53 and p63&#947; antibodies.</p></caption><graphic xlink:href="gkn132f6"/></fig>
S100A2 was described as a potential tumor suppressor (14). Therefore, we tested if regulation of S100A2 expression may be connected to DNA damage through p63. It had been observed earlier that p63 expression can be induced by DNA damage (59). Consistent with these results we found enhanced expression of TAp63 mRNA upon treatment of HepG2 hepatocellular carcinoma cells with doxorubicin for 24 to 48 hours. Interestingly, in line with TAp63 expression also S100A2 mRNA expression increases (Figure 6A). Of note is that mRNA levels of DeltaNp63 and TAp73 isoforms did not change significantly in this experiment (data not shown). Figure 6.Recruitment of p63gamma protein to the S100A2 promoter may connect S100A2 expression to DNA damage. (A) TAp63gamma and S100A2 mRNA expression increase after DNA damage. Real-time RT-PCR measurements of S100A2 and TAp63 mRNAs from doxorubicin-treated HepG2 cells. Relative mRNA levels were normalized to expression of GAPDH mRNA. Cells before treatment were employed as control. Control levels were set to 100%. Times of doxorubicin treatment are indicated. (B) Western blot analyses of lysates from p53-positive HepG2 and p53-negative Hep3B cells after doxorubicin-induced DNA damage. Controls contain samples taken before treatment. Doxorubicin-treated samples were analyzed after 24 h or 48 h. Detection of beta-actin served as a loading control. (C) Expression of S100A2 mRNA correlates with an increase of TAp63 mRNA after doxorubicin-induced DNA damage in p53-negative Hep3B cells. Relative mRNA levels were measured by real-time RT-PCR. Expression of GAPDH was used for normalization. S100A2 mRNA from untreated control cells was set to 100%. In control samples no TAp63 mRNA was detectable. Therefore, the TAp63 mRNA measurement at 24 h was employed as the 100% reference. (D) Chromatin immunoprecipitation (ChIP) assays of p53 and p63gamma proteins binding to the S100A2 promoter in HepG2 cells following DNA damage. Control and doxorubicin-treated cells were prepared as described above. Lanes are input (i), no antibody (n), p53 and p63gamma antibodies.
###end p 55
###begin p 56
###xml 39 45 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 67 73 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 101 102 97 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 104 114 100 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;</italic>
###xml 119 125 111 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 202 208 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 213 218 205 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 317 322 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 458 459 450 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 750 751 739 740 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 767 773 756 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 810 815 799 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 957 962 946 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 991 997 980 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1071 1076 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1113 1118 1102 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1181 1182 1170 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1272 1278 1257 1263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
Recruitment of p63gamma protein to the S100A2 promoter may connect S100A2 expression to DNA damage. (A) TAp63gamma and S100A2 mRNA expression increase after DNA damage. Real-time RT-PCR measurements of S100A2 and TAp63 mRNAs from doxorubicin-treated HepG2 cells. Relative mRNA levels were normalized to expression of GAPDH mRNA. Cells before treatment were employed as control. Control levels were set to 100%. Times of doxorubicin treatment are indicated. (B) Western blot analyses of lysates from p53-positive HepG2 and p53-negative Hep3B cells after doxorubicin-induced DNA damage. Controls contain samples taken before treatment. Doxorubicin-treated samples were analyzed after 24 h or 48 h. Detection of beta-actin served as a loading control. (C) Expression of S100A2 mRNA correlates with an increase of TAp63 mRNA after doxorubicin-induced DNA damage in p53-negative Hep3B cells. Relative mRNA levels were measured by real-time RT-PCR. Expression of GAPDH was used for normalization. S100A2 mRNA from untreated control cells was set to 100%. In control samples no TAp63 mRNA was detectable. Therefore, the TAp63 mRNA measurement at 24 h was employed as the 100% reference. (D) Chromatin immunoprecipitation (ChIP) assays of p53 and p63gamma proteins binding to the S100A2 promoter in HepG2 cells following DNA damage. Control and doxorubicin-treated cells were prepared as described above. Lanes are input (i), no antibody (n), p53 and p63gamma antibodies.
###end p 56
###begin p 57
###xml 226 234 226 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 253 259 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 327 333 327 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 436 441 436 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 481 486 481 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 568 573 568 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 578 584 578 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 617 625 617 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 665 674 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;Np63</italic>
###xml 679 684 675 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp73</italic>
HepG2 cells are positive for p53 protein expression. In addition to these cells we also tested the p53-negative liver cell line Hep3B for p53-protein induction after DNA damage. As expected, only in HepG2 cells p53 increases (Figure 6B). We examined if S100A2 expression also changes independently of p53. Also in Hep3B cells, S100A2 mRNA expression is induced when the p53-negative cells are treated with doxorubicin. Furthermore, the TAp63 mRNA level increases as well. However, TAp63 expression is not detectable in untreated cells, hampering a correlation between TAp63 and S100A2 expression as cause and effect (Figure 6C). Also in this cell system, levels of DeltaNp63 and TAp73 mRNAs did not change (data not shown).
###end p 57
###begin p 58
###xml 70 76 70 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 86 93 86 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 332 338 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 348 355 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 438 446 426 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 517 523 501 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 596 604 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 665 673 649 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 738 744 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 795 800 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
We wished to correlate expression of p63 proteins with binding to the S100A2 promoter in vivo by ChIP assays. However, p53-independent analysis of p63gamma-protein binding was not detectable likely due to low endogenous protein amounts (data not shown). Nevertheless, in HepG2 cells we could show binding of p63gamma protein to the S100A2 promoter in vivo following DNA damage. Recruitment of p63gamma is not observed in untreated cells (Figure 6D). Distinct from binding of p63gamma is the recruitment of p53 to the S100A2 promoter. p53 binds already to the promoter in cells before DNA damage (Figure 6D) although p53 is induced only after doxorubicin treatment (Figure 6B). In conclusion, binding of endogenous p63gamma protein to the S100A2 promoter matches with enhanced mRNA expression of TAp63 isoforms after doxorubicin-induced DNA damage.
###end p 58
###begin title 59
DISCUSSION
###end title 59
###begin p 60
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 539 541 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 630 632 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 65 70 <span type="species:ncbi:9606">human</span>
In contrast to p53, mutations of p63 are not frequently found in human cancer. Therefore, p63 is not a classical tumor suppressor despite strong structural homologies to p53 (60). Elucidating other possible p63 functions is difficult due to the presence of various p63 splice variants and their divergent expression pattern. The TAp63gamma protein closely resembles p53. One reason for the similarity is its lack of an inhibitory domain present in the alpha variants. TAp63gamma is found to be a very potent activator of p53 target genes (33) and seems to be able to enforce tumor suppressive mechanisms in which p53 is involved (34).
###end p 60
###begin p 61
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 135 138 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p63</italic>
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 213 216 <span type="species:ncbi:9606">man</span>
In addition to a possible function as a tumor suppressor, it was discovered that p63 plays a role in development (36,40). Heterozygous p63 germ line mutations cause several skin and other developmental defects in man (39,58). These observations suggest for p63 other transcriptional targets than for p53.
###end p 61
###begin p 62
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 130 136 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 173 183 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63&#947;</italic>
###xml 230 238 222 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 300 308 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 340 346 332 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 405 413 393 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 500 508 484 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 510 518 494 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 571 577 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 587 594 567 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 613 621 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 661 667 641 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 707 708 680 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 835 843 808 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 956 962 929 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1013 1014 986 987 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1045 1051 1018 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1082 1091 1047 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figures 1</xref>
###xml 1096 1097 1061 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 1134 1135 1099 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1681 1682 1632 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1802 1808 1749 1755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1867 1875 1814 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
Here we identify S100A2 as a transcriptional target of p63. Particularly the p63 variant TAp63gamma is rather active in enhancing S100A2 expression. Selective expression of TAp63gamma leads to a dramatic increase in mRNA amounts (Figure 1A) and subsequently to enhanced expression of S100A2 protein (Figure 1B). A novel binding site in the S100A2 promoter is essential for TAp63gamma-mediated activation (Figure 2). We demonstrated that TAp63gamma binds to this element in a sequence-specific manner in vitro (Figure 3). Furthermore, the recruitment of TAp63gamma to the S100A2 promoter in vivo was demonstrated (Figure 4). A recent report showed activation of S100A2 transcription by p73alpha and p73beta (3). Interestingly, we could show that the newly identified p63-response element is the activating site also for TAp73 proteins (Figure 2E). However, an additional element relevant for part of the p73-dependent activation in the second intron of the S100A2 gene, as discussed by others, cannot be excluded (3). We did not observe a strong S100A2 repression by DeltaNp63alpha (Figures 1 and 2E) as detected by other researchers (3). This may be caused by different experimental approaches. Lapi and coworkers employed firefly luciferase for measurement of reporter activity and beta-galactosidase for normalization instead of the firefly/Renilla-luciferase combination used here. The difference in protein stability between luciferase and beta-galactosidase may result in distortion of relative reporter activities. Other differences are the use of a DNA-binding-deficient mutant of DeltaNp63alpha as a control instead of empty vector and employment of distinct cell systems (3). However, Lapi and coworkers observed under their experimental conditions that TAp63alpha is not able to activate the S100A2 promoter which is perfectly consistent with our findings (Figure 2E).
###end p 62
###begin p 63
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 55 57 55 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 105 111 105 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 164 170 164 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 271 279 267 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 447 455 439 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
S100A2 is known to be a transcriptional target of p53 (20). Consistent with this we find an induction of S100A2 mRNA after expression of p53, but activation of the S100A2 promoter by p53 was substantially lower than the increase in expression after TAp63gamma induction (Figure 2). Furthermore, on the protein level S100A2 increased after TAp63gamma expression, whereas an equivalent protein induction was not detectable following p53 expression (Figure 1B). These findings suggest that TAp63gamma is a more potent transcriptional activator than p53 also implying that regulation through p63 generally may be more relevant for S100A2 function.
###end p 63
###begin p 64
###xml 168 177 164 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figures 2</xref>
###xml 183 184 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 339 341 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 342 344 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 515 521 511 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 655 657 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
We demonstrated that changing one nucleotide in the core of the newly identified binding element 2 is sufficient to differentiate between binding of p53 or TAp63gamma (Figures 2D and 3B). These observations are in line with previously published results which demonstrate that p63 preferentially binds to degenerate p53 consensus elements (42,43). This mechanism appears to be important for differentiating functions of p63 versus p53. Furthermore, the evolutionary conservation of the identified binding element in S100A2 promoters from different species (data not shown) suggests an essential biological relevance of the TAp63gamma-dependent regulation (61).
###end p 64
###begin p 65
###xml 252 257 252 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37 B38 B39">37&#8211;39</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 375 381 375 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 543 551 539 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 673 679 669 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 762 768 754 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 819 827 807 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1061 1063 1049 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 1156 1162 1144 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 146 151 <span type="species:ncbi:9606">human</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
###xml 935 943 <span type="species:ncbi:9606">patients</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1213 1221 <span type="species:ncbi:9606">patients</span>
One function of p63 is the regulation of developmental processes. Several mutations in the p63 DNA-binding domain are responsible for a family of human syndromes characterized by a combination of ectrodactyly, ectodermal dysplasia and facial clefting (37-39,58). These observations led us to test the influence of disease-related p63 mutants on transcriptional activation of S100A2. In reporter assays, we found an even stronger transcriptional activation employing two TAp63gamma mutants derived from SHFM patients compared to wild-type p63 (Figure 5). In contrast, three p63 mutants responsible for the EEC syndrome had essentially lost their activation potential on the S100A2 promoter. A TAp63gamma mutant related to the ADULT syndrome yielded some residual S100A2 activation when compared to wild-type TAp63gamma (Figure 5). Interestingly, these observations correlate with severity of the epidermal syndrome phenotype since SHFM patients, in contrast to patients suffering from EEC and ADULT syndromes, are characterized by a lack of epidermal dysplasia (62). Therefore, it is tempting to speculate that the ability of p63 to stimulate expression of S100A2 plays a role in developing the phenotype of these patients. Further research is required to establish a stronger link.
###end p 65
###begin p 66
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 185 191 185 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 255 260 255 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15 B16 B17 B18">15&#8211;18</xref>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 338 343 338 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21 B22 B23 B24 B25 B26">21&#8211;26</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 711 717 711 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 853 855 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 934 940 934 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 973 981 973 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1018 1024 1018 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1076 1082 1072 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1093 1101 1089 1097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1419 1424 1407 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1600 1606 1584 1590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1641 1649 1625 1633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1766 1772 1750 1756 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 1814 1819 1798 1803 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TAp63</italic>
###xml 1859 1867 1843 1851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1920 1926 1904 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 2061 2063 2041 2043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 2256 2262 2232 2238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">maspin</italic>
###xml 2281 2283 2257 2259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 144 147 <span type="species:ncbi:9606">man</span>
S100A2 was identified as a potential tumor suppressor by subtractive hybridization between normal and tumor-derived mammary epithelial cells in man (14). Consistent with these findings S100A2 expression is markedly downregulated in several tumor tissues (15-18). However, it was shown that S100A2 expression is increased in other tumors (21-26). It was discussed that overexpression is an early event in tumorigenesis. Furthermore, a physical interaction between S100A2 and p53 proteins enhances transcriptional activity of p53 which implies antitumorigenic properties of S100A2 (27). A possible interaction also between p63 and S100A2 proteins has not yet been investigated. Recently, it was demonstrated that S100A2 expression is able to diminish expression of Cox-2 protein which provides further evidence for a tumor suppressive function of S100A2 (28). Interestingly, in line with these observations we showed that expression of S100A2 increases following DNA damage (Figure 6A and C). The enhanced expression of S100A2 correlates with binding of p63gamma protein to the S100A2 promoter (Figure 6D). Generally, detection of different p63 isoforms on the mRNA and protein levels is difficult. It is possible to differentiate between TAp63 and DeltaNp63 mRNA variants. On the protein level we were able to observe p63gamma versus total p63 protein expression. After DNA damage we exclusively find an increase in the TAp63 isoforms on the mRNA level. Combining these observations with the data from the ChIP assays suggests that TAp63gamma is induced after DNA damage and subsequent binding to the S100A2 promoter mediates its regulation (Figure 6D). Supportive of this notion is the finding that p53-negative Hep3B cells also show an increase in transcription of S100A2 together with enhanced expression of the TAp63 isoforms after DNA damage is observed (Figure 6C). In conclusion, it is possible that regulation of S100A2 transcription by TAp63gamma is a supporting mechanism to complement and enhance cellular response in preventing tumor transformation (34). This is consistent with earlier observations implying that TAp63gamma is able to substitute partially p53 function in hepatocellular carcinomas lacking p53 expression by transactivating the maspin tumor suppressor (55).
###end p 66
###begin p 67
###xml 25 31 25 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 196 202 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 418 424 406 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 493 499 477 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 569 575 553 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S100A2</italic>
###xml 341 349 <span type="species:ncbi:9606">patients</span>
In summary, we show that S100A2 is a novel transcriptional target of the p63 splice variant TAp63gamma. The regulation is mediated by a novel and strongly conserved transcriptional element in the S100A2 promoter which is bound by TAp63gamma but not by p53. Transcriptional properties of p63 mutants derived from EEC, ADULT and SHFM syndrome patients yield evidence for a role of a TAp63gamma-mediated transcription of S100A2 in developmental processes. Recruitment of p63gamma proteins to the S100A2 promoter following DNA damage correlates with enhanced expression of S100A2 and suggest a function in tumor suppression.
###end p 67
###begin title 68
SUPPLEMENTARY DATA
###end title 68
###begin p 69
 are available at NAR Online.
###end p 69
###begin title 70
Supplementary Material
###end title 70
###begin title 71
[Supplementary Data]
###end title 71
###begin title 72
ACKNOWLEDGEMENTS
###end title 72
###begin p 73
We thank Jana Lorenz for technical assistance, Drs Bert Vogelstein and Beat W. Schafer for generously providing cells and plasmids. G.A.M. was the recipient of a graduate fellowship provided by the Freistaat Sachsen. This work was supported by a grant from the Interdisciplinary Center for Clinical Research (IZKF) at the University of Leipzig (to K.E.). Funding to pay the Open Access publication charges for this article was provided by the IZKF.
###end p 73
###begin p 74
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 74
###begin title 75
REFERENCES
###end title 75
###begin article-title 76
Isolation of a new member of the S100 protein family - amino-acid sequence, tissue, and subcellular-distribution
###end article-title 76
###begin article-title 77
###xml 77 82 <span type="species:ncbi:9606">human</span>
Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions
###end article-title 77
###begin article-title 78
S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiation
###end article-title 78
###begin article-title 79
###xml 70 75 <span type="species:ncbi:9606">human</span>
Distinct subcellular localization of calcium binding S100 proteins in human smooth muscle cells and their relocation in response to rises in intracellular calcium
###end article-title 79
###begin article-title 80
Subcellular distribution of S100 proteins in tumor cells and their relocation in response to calcium activation
###end article-title 80
###begin article-title 81
###xml 128 133 <span type="species:ncbi:9606">human</span>
Differential responses of S100A2 to oxidative stress and increased intracellular calcium in normal, immortalized, and malignant human keratinocytes
###end article-title 81
###begin article-title 82
Evolution of the Ef-hand family of proteins
###end article-title 82
###begin article-title 83
###xml 42 47 <span type="species:ncbi:9606">human</span>
Biochemical characterization of S100A2 in human keratinocytes: Subcellular localization, dimerization, and oxidative cross-linking
###end article-title 83
###begin article-title 84
###xml 28 33 <span type="species:ncbi:9606">human</span>
Binding of Ca2+ and Zn2+ to human nuclear S100A2 and mutant proteins
###end article-title 84
###begin article-title 85
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
###xml 27 30 <span type="species:ncbi:9606">man</span>
S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)
###end article-title 85
###begin article-title 86
Physical mapping of a functional cluster of epidermal differentiation genes on chromosome-1Q21
###end article-title 86
###begin article-title 87
The S100 protein family - history, function, and expression
###end article-title 87
###begin article-title 88
Intracellular and extracellular roles of s100 proteins
###end article-title 88
###begin article-title 89
Positive selection of candidate tumor-suppressor genes by subtractive hybridization
###end article-title 89
###begin article-title 90
###xml 80 85 <span type="species:ncbi:9606">human</span>
Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis
###end article-title 90
###begin article-title 91
Down-regulation of a member of the S100 gene family in mammary-carcinoma cells and reexpression by azadeoxycytidine treatment
###end article-title 91
###begin article-title 92
###xml 84 89 <span type="species:ncbi:9606">human</span>
Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
###end article-title 92
###begin article-title 93
Down-regulation of S100A2 in lymph node metastases of head and neck cancer
###end article-title 93
###begin article-title 94
Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site specific hypermethylation
###end article-title 94
###begin article-title 95
###xml 34 39 <span type="species:ncbi:9606">human</span>
Transcriptional activation of the human S100A2 promoter by wild-type p53
###end article-title 95
###begin article-title 96
Gastric cancers overexpress S100A calcium-binding proteins
###end article-title 96
###begin article-title 97
Coordinately up-regulated genes in ovarian cancer
###end article-title 97
###begin article-title 98
###xml 49 54 <span type="species:ncbi:9606">human</span>
Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays
###end article-title 98
###begin article-title 99
Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma
###end article-title 99
###begin article-title 100
S100A2, a putative tumor suppressor gene, regulates in vitro squamous cell carcinoma migration
###end article-title 100
###begin article-title 101
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer
###end article-title 101
###begin article-title 102
The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity
###end article-title 102
###begin article-title 103
Cyclooxygenase-2 is involved in S100A2-mediated tumor suppression in squamous cell carcinoma
###end article-title 103
###begin article-title 104
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress
###end article-title 104
###begin article-title 105
A novel protein with strong homology to the tumor suppressor p53
###end article-title 105
###begin article-title 106
A second p53-related protein, p73L, with high homology to p73
###end article-title 106
###begin article-title 107
###xml 6 11 <span type="species:ncbi:9606">human</span>
A new human p53 homologue
###end article-title 107
###begin article-title 108
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
###end article-title 108
###begin article-title 109
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
###end article-title 109
###begin article-title 110
The p63 gene in EEC and other syndromes
###end article-title 110
###begin article-title 111
p63 is a p53 homologue required for limb and epidermal morphogenesis
###end article-title 111
###begin article-title 112
Pattern of p63 mutations and their phenotypes-update
###end article-title 112
###begin article-title 113
p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation
###end article-title 113
###begin article-title 114
###xml 77 83 <span type="species:ncbi:9606">humans</span>
Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans
###end article-title 114
###begin article-title 115
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
###end article-title 115
###begin article-title 116
P63 and P73: P53 mimics, menaces and more
###end article-title 116
###begin article-title 117
Derivation of the consensus DNA-binding sequence for p63 reveals unique requirements that are distinct from p53
###end article-title 117
###begin article-title 118
Differential recognition of response elements determines target gene specificity for p53 and p63
###end article-title 118
###begin article-title 119
###xml 83 88 <span type="species:ncbi:9606">human</span>
Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73
###end article-title 119
###begin article-title 120
Identification and classification of p53-regulated genes
###end article-title 120
###begin article-title 121
###xml 61 66 <span type="species:ncbi:9606">human</span>
Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers
###end article-title 121
###begin article-title 122
###xml 38 43 <span type="species:ncbi:9606">human</span>
Mutational analysis of p73 and p53 in human cancer cell lines
###end article-title 122
###begin article-title 123
A single cell cycle genes homology region (CHR) controls cell cycle-dependent transcription of the cdc25C phosphatase gene and is able to cooperate with E2F or Sp1/3 sites
###end article-title 123
###begin article-title 124
###xml 49 54 <span type="species:ncbi:9606">human</span>
Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
###end article-title 124
###begin article-title 125
The tumour suppressor protein p53 can repress transcription of cyclin B
###end article-title 125
###begin article-title 126
###xml 128 133 <span type="species:ncbi:9606">human</span>
Three CCAAT-boxes and a single cell cycle genes homology region (CHR) are the major regulating sites for transcription from the human cyclin B2 promoter
###end article-title 126
###begin article-title 127
Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a CHR-dependent repression mechanism
###end article-title 127
###begin article-title 128
A polymorphic microsatellite that mediates induction of PIG3 by p53
###end article-title 128
###begin article-title 129
c-Myc target gene specificity is determined by a post-DNA binding mechanism
###end article-title 129
###begin article-title 130
TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor
###end article-title 130
###begin article-title 131
Definition of a consensus binding site for p53
###end article-title 131
###begin article-title 132
Regulation of the specific DNA-binding function of P53
###end article-title 132
###begin article-title 133
Splitting p63
###end article-title 133
###begin article-title 134
The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells
###end article-title 134
###begin article-title 135
p63: oncogene or tumor suppressor?
###end article-title 135
###begin article-title 136
###xml 100 105 <span type="species:ncbi:9606">human</span>
Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells
###end article-title 136
###begin article-title 137
Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27
###end article-title 137

